PROMOMED was the first in Russia to attract financing with the help of new format bonds

April 29, 2025, Moscow – PJSC PROMOMED (MOEX: PRMD) (formerly "PROMOMED", the "Company", and together with its subsidiaries, the "Group") announces the creation and placement of a new investment product, a structural bond that provides full capital protection and is linked to cost growth Company shares. The volume of attraction amounted to more than 1.6 billion rubles and confirmed the high interest of investors in the PROMOTIONAL growth strategy and the new investment product.

As a result of the transaction, the Company attracted financing in the amount of more than 1.6 billion rubles to continue financing its investment program aimed at developing innovative medicines.

The income on structural bonds is linked to the growth of PROMOMED's capitalization, and capital protection is provided by a subsidiary of PJSC PROMOMED, the operating company PROMOMED DM LLC, which has a credit rating of "ruA-" from Expert RA.

The deal attracted record demand from qualified investors for such instruments: more than 400 qualified investors participated in the offering.

The issuer of the bonds was a specialized financial company, SFO CADMIUM CREDIT LLC, managed by FOCUS Management, one of the best management companies in the Siberian Federal District according to Cbonds Awards 2024.

The technical placement took place on April 28, 2025. The bond placement price was set at RUB 25,119.00. based on the weighted average value of shares of PJSC PROMOMED following the results of the main trading session on the Moscow Stock Exchange on April 24, 2025. For the purpose of settlement of the transaction, one bond accounts for 60 shares of the Company.

Alexander Yefremov, General Director of PJSC PROMOMED:

"The entire ecosystem of PROMOMED is saturated with innovations. Most recently, we told our investors about the Group's latest developments, excellence in manufacturing technologies, the use of artificial intelligence in the Company's operations, and an innovative product delivery program to our patients – I mean, a subscription program for anti-obesity and diabetes drugs. PROMOMED today announces the creation of a new investment product for the Russian stock market, which provides capital protection and is linked to the growth of the Company's share price. More than 400 qualified investors have already purchased structural bonds, thereby confirming the high interest in PROMOMED shares. This transaction has allowed even more investors to participate in the market-leading growth of a successful biopharmaceutical company. We see that the growing interest in innovative companies is combined with a demand for secure investment instruments, which is exactly the product we have introduced to the market."

This transaction expands the Company's portfolio of financing instruments and reduces the cost of borrowing.

The new structural bond is a continuation of the Company's strategy of expanding the investor base, increasing investment transparency and increasing shareholder value.

LECAP acted as a consultant for the transaction (https://lecap.ru ), more than
For 15 years, she has been leading the largest projects in the equity and debt capital, structural finance and M&A markets.

About the Company

PJSC PROMOMED is a leading innovative biopharmaceutical company with the potential for significant growth in promising segments of the pharmaceutical market.

The Company's structure includes its own unique world-class R&D center and a high–tech enterprise, the Biochemist plant. Thanks to this, PROMOMED implements the concept of a full production cycle "from Idea to Molecule, from Molecule to Patient", promptly responds to the current needs of the industry, and also implements the latest technologies to create innovative medicines. The company develops a diversified portfolio of more than 350 medicines in the TOP 10 segments of the pharmaceutical market. The Company's portfolio includes "blockbuster" drugs and innovative biotechnological drugs that have no analogues on the Russian market. Based on its own developments, the Company produces drugs for the treatment of socially significant diseases: oncology, diabetes, obesity, neurology, infectious diseases, rheumatology, etc. Thanks to its own innovative chemical technologies and biotechnologies, as well as modern production facilities, the Company is an active participant in the system of ensuring national drug safety and import independence of the country.

Contacts

For investors	For the media
ir@promomed.pro	pr@promomed.pro

Statement of limitation of liability

This message and the information contained therein are not:

• an offer to purchase any securities,
• an invitation to make offers for the purchase of any securities,
• as part of such offers or invitations,
• securities advertising in the Russian Federation or other jurisdictions,
• by encouraging or recommending transactions,
• it is also not subject to interpretation as such.

Neither this communication nor any part of it is the basis for concluding any transaction or incurring any obligation, they cannot be used in connection with any transactions or obligations or serve as an incentive to conclude any transactions or assume any obligations.

Neither this announcement nor any part of it should serve as a basis for making any investment decisions.

The publication of this communication does not imply investment consulting (in the meaning defined in the legislation of the Russian Federation (including Federal Law No. 39-FZ of April 22, 1996 "On the Securities Market"). The information provided in this message is not an individual investment recommendation, and the financial instruments or transactions mentioned in it may not meet your investment profile and investment goals (expectations). It is your task to determine whether a financial instrument or operation matches your interests, investment goals, investment horizon, and acceptable risk level. PJSC PROMOMED (hereinafter referred to as the Company) is not responsible for possible losses in the event of transactions or investments in financial instruments mentioned in this information, and does not recommend using this information as the only source of information when making an investment decision.

Before making an investment decision on making or not making transactions with the Company's shares, it is necessary, among other things, to familiarize yourself with the information disclosed on the Company's web page.https://e-disclosure.ru/portal/company.aspx?id=38533.

The information contained in this announcement may include estimates and other forward-looking statements regarding the intentions, plans, future events, financial, operational or other activities of the Group. Actual events, calculations and results of their activities may differ materially from those contained or anticipated in the forward-looking statements, words and expressions provided in this communication or related materials due to the influence of various external and internal factors (general economic conditions; risks associated with the specifics of the Company's activities, including those that cannot be controlled by the Company; changes in market conditions in the industry in which the Company and the Group operate; geopolitical and other factors and risks). The indication of goals, potential, growth opportunities or other indicators is not a guarantee of the realization of these goals, potential, opportunities.

The methodology for determining and calculating the operational and financial indicators of a Company may differ from the methodology used by other individuals, companies or organizations.

The Company or persons belonging to the Group, their directors, participants (shareholders), employees, representatives do not provide any guarantees or assurances confirming the accuracy, completeness or unambiguous nature of the information and information contained in this communication or related materials, and do not assume any obligations or obligations to updating them.